NIPH Clinical Trials Search

UMIN ID: C000000045

Registered date:06/08/2005

A phase I/II study of percutaneous radiofrequency ablation for malignant lung tumor (JIVROSG-0203)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedUnresectable malignant lung tumor.
Date of first enrollment2004/04/01
Target sample size33
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)A radiofrequency needle is inserted into the lung tumor percutaneously, and then, radiofrequency tumor ablation is performed.


Primary OutcomeAdverse events
Secondary OutcomeDecrease of tumor accumulation on the image obtained by FDG-PET.

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Unmeasurable lesion on CT. 2) Lesion with ground-glass opacity on CT. 3) Lesion adjacent to heart, mediastinum, pleura and vessel or bronchus more than 5mm in diameter. 4) Active inflammation or infection. 5) Fever above 38 degrees Celsius. 6) Cardiac pacemaker. 7) Anti-coagulant medication. 8) Severe dysfunction in the contra-lateral lung. 9) Pulmonary hypertension. 10) Difficulty of normal activity due to cerebrovascular disease, prior neurosurgery or trauma. 11) Pregnancy.

Related Information


public contact
Name Yasuaki Arai
Address 5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan Japan
Telephone 03-3542-2511
Affiliation JIVROSG, Coordinating Office Division of Diagnostic Radiology, National Cancer Center Hospital
scientific contact
Name Toshiyuki Matsuoka
Address 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan Japan
Telephone 06-6645-3831
Affiliation Osaka City University Medical School Department of Radiology